$146.63
Value $363B
MRK and SBC stock compared: price, dividend, valuation and results, from SEC filings.
$146.63
Value $363B
$6.58
Value $675M
Merck & Company (MRK) has a market value of $363B and SBC Medical Group (SBC) $675M. Over the last year, with dividends, MRK moved +62.5% and SBC +98.8%. The P/E is 147.8 for MRK and 13.0 for SBC. Dividend yield: MRK 2.32%, SBC none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$363B
SBC$675M
MRK is 537 times SBC
Revenue, 12 months
MRK$67.4B
SBC$190M
MRK is 354 times SBC
Net income, 12 months
MRK$2.5B
SBC$52M
MRK is 47 times SBC
Operating margin
MRK–
SBC39.9%
ROIC
MRK3.9%
SBC16.3%
12.4 points apart
P/E
MRK147.8
SBC13.0
MRK is 11 times SBC
Dividend yield
MRK2.3%
SBC0.0%
2.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+57.6%
SBC-38.2%
| Period | MRKWith dividends | SBCWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +62.5%Price +57.8% | +98.8%Price +98.8% |
| 3 years since November 16, 2023 | +57.6%+16.4% a yearPrice +43.8% | -38.2%-14.8% a yearPrice -38.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanySBCSBC Medical Group
| Price | $146.63 | $6.58 |
|---|---|---|
| Market value | $363B | $675M |
| Enterprise value (EV) | $407B | $519M |
| P/E | 147.8 | 13.0 |
| P/E, 5-year median | 14.8 | 11.6 |
| P/B | 8.1 | 2.4 |
| EV/EBIT | 85.4 | 6.8 |
| Free cash flow yield | 4.1% | 14.9% |
| Revenue, 12 months | $67.4B | $190M |
|---|---|---|
| Net income, 12 months | $2.5B | $52M |
| Free cash flow, 12 months | $14.7B | $100M |
| Earnings per share, 12 months | $0.98 | $0.50 |
| Revenue growth, year on year | 1.3% | -15.5% |
| Revenue growth a year, past | +9.4%over 5 years | -5.3%over 2 years |
| EPS growth a year, past | +21.2%over 5 years | +9.1%over 2 years |
| Gross margin | 71.8% | 72.2% |
|---|---|---|
| Operating margin | – | 39.9% |
| Net margin | 3.6% | 27.3% |
| ROIC | 3.9% | 16.3% |
| ROE | 5.2% | 19.9% |
| Cash | $9.7B | $199M |
|---|---|---|
| Total debt | $53.8B | $53M |
| Net debt / EBITDA | 5.7 | -2.0 |
| Interest cover | 2.4× | 181.9× |
| Dividend yield | 2.3% | – |
|---|---|---|
| Dividend per share, 12 months | $3.40 | – |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.4% | 0.7% |
| Shareholder yield | 3.7% | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($363B) is about 537.1 times SBC Medical Group ($675M), at today's prices.
Since November 16, 2023, MRK's price moved +43.8% and SBC's -38.2%. With dividends: MRK +57.6% (+16.4% a year), SBC -38.2% (-14.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.32% for Merck & Company and none for SBC Medical Group. Over the last twelve months they paid $3.40 and – per share.
At today's price, the P/E is 147.8 for MRK and 13.0 for SBC. The median of the last five years was 14.8 and 11.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.6% for Merck & Company and 27.3% for SBC Medical Group, and the operating margin – and 39.9%. Revenue was $67.4B and $190M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.